MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX)

Price$18.82

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)31.61%

Price vs S&P 500 (4W)9.67%

VGM Score54.32

Market Capitalization$1.41B

All Metrics

Book Value / Share (Quarterly)$3.52

P/TBV (Annual)55.54x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-3.11

Price vs S&P 500 (YTD)34.59%

EPS (TTM)$-3.87

10-Day Avg Trading Volume0.79M

EPS Excl Extra (TTM)$-3.87

EPS (Annual)$-3.53

ROI (Annual)-26.61%

Cash / Share (Quarterly)$4.96

ROA (Last FY)-24.88%

EBITD / Share (TTM)$-3.98

Cash Flow / Share (Annual)$-1.86

P/B Ratio5.56x

P/B Ratio (Quarterly)5.26x

Net Income / Employee (Annual)$-1,748,600

Net Interest Coverage (TTM)-30.69x

ROA (TTM)-60.52%

EPS Incl Extra (Annual)$-3.53

Current Ratio (Annual)21.55x

Quick Ratio (Quarterly)7.89x

3-Month Avg Trading Volume1.12M

52-Week Price Return-50.77%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$7.93

52-Week High$62.75

EPS Excl Extra (Annual)$-3.53

26-Week Price Return47.54%

Quick Ratio (Annual)21.52x

13-Week Price Return8.48%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)8.60x

Enterprise Value$1.21B

Revenue / Employee (Annual)$0

Cash / Share (Annual)$7.11

3-Month Return Std Dev63.04%

Net Income / Employee (TTM)$-1,977,600

ROE (Last FY)-26.61%

Net Interest Coverage (Annual)-26.20x

EPS Basic Excl Extra (Annual)$-3.53

Total Debt / Equity (Quarterly)0.39x

EPS Incl Extra (TTM)$-3.87

ROI (TTM)-67.59%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$1.25

Price vs S&P 500 (52W)-78.98%

Year-to-Date Return45.52%

5-Day Price Return5.44%

EPS Normalized (Annual)$-3.53

Month-to-Date Return17.09%

Cash Flow / Share (TTM)$-1.19

EBITD / Share (Annual)$-3.76

LT Debt / Equity (Quarterly)0.39x

EPS Basic Excl Extra (TTM)$-3.87

P/TBV (Quarterly)6.39x

P/B Ratio (Annual)7.74x

Book Value / Share (Annual)$7.10

Price vs S&P 500 (13W)-1.26%

Beta1.05x

Revenue / Share (TTM)$0.00

ROE (TTM)-85.61%

52-Week Low$5.95

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.98est. -0.91

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.75

3.78

4.00

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
MLTXMoonLake Immunotherapeutics Class A Ordinary Shares	—	—	C	$18.82
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing SLK, a tri-specific Nanobody that inhibits IL-17A and IL-17F to treat inflammatory skin and joint diseases. Clinical data suggest SLK has potential for disease modification in dermatology and rheumatology indications where IL-17A and IL-17F drive pathophysiology.